A Randomized, Double-Blind, Multicenter, Equivalence Study of ONS-3010 and Humira® for the Treatment of Patients with Moderate to Severe Plaque Psoriasis

Trial Profile

A Randomized, Double-Blind, Multicenter, Equivalence Study of ONS-3010 and Humira® for the Treatment of Patients with Moderate to Severe Plaque Psoriasis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Oncobiologics
  • Most Recent Events

    • 16 Jun 2016 According to an Oncobiologics media release, the company has received the first of its European Union (EU) clinical trial authorization (CTA) approvals, including in the United Kingdom, Germany and Spain, for the biosimilarity study portion of this trial.
    • 01 Jun 2016 Status changed from planning to recruiting.
    • 06 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top